142 related articles for article (PubMed ID: 21817962)
21. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Cho SW; Kim CG; Kim JW
Retina; 2013; 33(10):2126-32. PubMed ID: 23609123
[TBL] [Abstract][Full Text] [Related]
22. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354
[TBL] [Abstract][Full Text] [Related]
23. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor.
Lee MY; Lee WK; Baek J; Kwon OW; Lee JH
Am J Ophthalmol; 2013 Aug; 156(2):343-8. PubMed ID: 23664208
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.
Kang HK; Yoon MH; Lee DH; Chin HS
Korean J Ophthalmol; 2012 Dec; 26(6):414-22. PubMed ID: 23204795
[TBL] [Abstract][Full Text] [Related]
25. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Kim M; Kim K; Kim DG; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(4):205-13. PubMed ID: 21893965
[TBL] [Abstract][Full Text] [Related]
26. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
[TBL] [Abstract][Full Text] [Related]
27. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Kim HS; Jang YS; Han JI; Lew YJ; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Dec; 156(6):1192-1200.e1. PubMed ID: 24011522
[TBL] [Abstract][Full Text] [Related]
28. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.
Hikichi T; Higuchi M; Matsushita T; Kosaka S; Matsushita R; Takami K; Ohtsuka H; Ariga H
Am J Ophthalmol; 2012 Jul; 154(1):117-124.e1. PubMed ID: 22465366
[TBL] [Abstract][Full Text] [Related]
29. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.
Brantley MA; Fang AM; King JM; Tewari A; Kymes SM; Shiels A
Ophthalmology; 2007 Dec; 114(12):2168-73. PubMed ID: 18054635
[TBL] [Abstract][Full Text] [Related]
30. Association of ARMS2/HTRA1 variants with polypoidal choroidal vasculopathy phenotype in a Korean population.
Park DH; Kim IT
Jpn J Ophthalmol; 2012 Jan; 56(1):60-7. PubMed ID: 21959923
[TBL] [Abstract][Full Text] [Related]
31. Adjusted retreatment of polypoidal choroidal vasculopathy after combination therapy: results at 3 years.
Jeon S; Lee WK; Kim KS
Retina; 2013 Jun; 33(6):1193-200. PubMed ID: 23508074
[TBL] [Abstract][Full Text] [Related]
32. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
Rouvas AA; Papakostas TD; Ntouraki A; Douvali M; Vergados I; Ladas ID
Retina; 2011 Mar; 31(3):464-74. PubMed ID: 20948458
[TBL] [Abstract][Full Text] [Related]
33. Photodynamic therapy for polypoidal choroidal vasculopathy.
Chhablani JK
Am J Ophthalmol; 2010 Nov; 150(5):754-5; author reply 755. PubMed ID: 21036213
[No Abstract] [Full Text] [Related]
34. Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy.
Nakata I; Tsujikawa A; Yamashiro K; Otani A; Ooto S; Akagi-Kurashige Y; Ueda-Arakawa N; Iwama D; Yoshimura N
Graefes Arch Clin Exp Ophthalmol; 2013 Apr; 251(4):1073-80. PubMed ID: 22923282
[TBL] [Abstract][Full Text] [Related]
35. Correlation of indocyanine green angiography and optical coherence tomography findings after intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ueno C; Gomi F; Sawa M; Nishida K
Retina; 2012; 32(10):2006-13. PubMed ID: 22772392
[TBL] [Abstract][Full Text] [Related]
36. Changes in fundus autofluorescence after treatments for polypoidal choroidal vasculopathy.
Yamagishi T; Koizumi H; Yamazaki T; Kinoshita S
Br J Ophthalmol; 2014 Jun; 98(6):780-4. PubMed ID: 24515988
[TBL] [Abstract][Full Text] [Related]
37. HALF-DOSE PHOTODYNAMIC THERAPY COMBINED WITH BEVACIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Lee JH; Lee WK
Retina; 2015 Aug; 35(8):1561-8. PubMed ID: 25768248
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
[TBL] [Abstract][Full Text] [Related]
39. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.
Yamashiro K; Tomita K; Tsujikawa A; Nakata I; Akagi-Kurashige Y; Miyake M; Ooto S; Tamura H; Yoshimura N
Am J Ophthalmol; 2012 Jul; 154(1):125-36. PubMed ID: 22465368
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
